Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.
纳武利尤单抗联合伊匹木单抗可诱导肾髓质癌超进展：II期试验结果和临床前证据。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-65462-z
Soeung Melinda, Yan Xinmiao, Zanca Ciro, Qian Jing, Karki Menuka, Duan Fei, Khan Hania, Zhang Li, Peng David H, Williams Mariah, He Rong, Chen Ziheng, Perelli Luigi, Chen Jianfeng, Tidwell Rebecca S, Chauhan Pankaj K, Le Courtney N, Lam Truong N A, Bhattacharya Nirjar, Shah Rutvi, Ho I-Lin, Gay Jason P, Carrillo Caroline C, Feng Ningping, Le Kang, Gao Guang, Perry Teresa L, Mseeh Faika, Jiang Yongying, Xu Quanyun A, Zacharias Niki Marie, Sheth Rahul A, Bathala Tharakeswara K, Rao Priya, Daw Najat C, Tripathi Durga N, Walker Cheryl L, Mohammad Mohammad M, Zhang Jianhua, Han Guangchun, Chu Yanshuo, Wang Ruiping, Dang Minghao, Dai Enyu, Peng Fuduan, Liu Yunhe, Jadhav Akshaya, Lang Wenhua, Arrechedera Claudio A, Clemente Leticia Campos, Parra Edwin R, Lu Hsinyi, Haymaker Cara L, Wistuba Ignacio I, Futreal Andrew, Viale Andrea, Soth Michael J, Jones Philip, Marszalek Joseph R, Heffernan Timothy, Draetta Giulio F, Tannir Nizar M, Gao Jianjun, Wang Linghua, Genovese Giannicola, Msaouel Pavlos
